Literature DB >> 19368854

No association between the promoter polymorphisms of PAI-1 gene and sporadic Alzheimer's disease in Chinese Han population.

Yan Lu1, Min Wang, Zheng Liu, Fen Wang, Yuwei Da, Jianping Jia.   

Abstract

Amyloid beta peptide (Abeta) accumulation is the major event in the brain of cases with Alzheimer's disease (AD). The serine protease plasmin, which is generated from the inactive zymogen plasminogen, could accelerate Abeta degradation, and thus may play a role in AD pathogenesis. It has been reported that the increasing of plasminogen activator inhibitor-1 (PAI-1) inhibits the activity of plasminogen activator and thus reduces the generation of plasmin in vivo. For seeking the correlation of the PAI-1 promoter with sporadic AD (SAD), we performed a case-control study in a group of Chinese Han population. In the study, we detected two polymorphisms, a G/A single base substitution polymorphism at -844bp (rs2227631) and a single guanosine deletion/insertion 4G/5G polymorphism at -675bp (rs1799889) upstream from the start of transcription. Direct sequencing was used for genotyping in 324 SAD patients and 278 controls. We failed to find any associations between these two polymorphisms and SAD even after stratified by age of onset, gender and apolipoprotein E (APOE) epsilon4 status. Our data do not support that there is an association between the PAI-1 promoter polymorphisms and SAD in the Chinese Han population.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19368854     DOI: 10.1016/j.neulet.2009.02.039

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  1 in total

1.  Association between plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism and risk of Alzheimer's disease, metabolic syndrome, and female infertility: A meta-analysis.

Authors:  Xin Zhang; Bai Gao; Bing Xu
Journal:  Medicine (Baltimore)       Date:  2020-12-11       Impact factor: 1.817

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.